Last reviewed · How we verify
NCT03789760
The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule
Phase 3 trial testing SaiLuoTong capsule in Vascular Dementia in 493 participants. Completed in 19 May 2024.
12 March 2024
Quick facts
| Lead sponsor | Shineway Pharmaceutical Co.,Ltd |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 493 |
| Start date | 10 April 2019 |
| Primary completion | 12 March 2024 |
| Estimated completion | 19 May 2024 |
| Sites | 29 locations across China |
Drugs / interventions tested
- SaiLuoTong capsule — full drug profile →
- placebo
Conditions studied
- Vascular Dementia — all drugs for Vascular Dementia →
Sponsor
Shineway Pharmaceutical Co.,Ltd — full company profile →
Who can join
Adults 40 to 75, any sex, with Vascular Dementia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
As a traditional Chinese medicine compound, SaiLuoTong capsule is proven to have beneficial effects on learning and memory ability in animal models of vascular dementia (VaD). According to the result of the phase II study, the efficacy of SaiLuoTong capsule in the treatment of patients with VaD was better than that of placebo group and no difference in safety. So the study hypothesis is also that SaiLuoTong capsule will be effective in the treatment of patients with VaD and will be well tolerated. The purpose of the study is to confirm the efficacy and safety of SaiLuoTong capsule on patients with mild to moderate VaD. The outcome measures include general cognitive function, executive function, daily living skills, and mental behavior changes of symptoms in VaD patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical Trials of New Drugs for Vascular Cognitive Impairment and Vascular Dementia.
Linh TTD, Hsieh YC, Huang LK, Hu CJ. · · 2022 · cited 39× · PMID 36232368 · DOI 10.3390/ijms231911067
Verify or expand the search:
- PubMed search for NCT03789760
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vascular Dementia
Currently open trials in the same condition.
- NCT07149038 — Evaluation of Cerogrin for Auricular Vagus Nerve Stimulation in Vascular Dementia or Vascular Mild Cognitive Impairment · NA · recruiting
- NCT06298474 — The BRAIN App (Phase 2 SBIR) · NA · recruiting
- NCT06862557 — Pulsed Electromagnetic Field Treatment With Dementia Patients · NA · recruiting
- NCT06416371 — Retinal Vessel Leakage in Cerebral Small Vessel Disease · recruiting
- NCT07259499 — Predictors of Emergency Department Use in Frail Patients · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03789760 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shineway Pharmaceutical Co.,Ltd
- Last refreshed: 17 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03789760.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing